Regulatory errors with endogenous agendas

American Journal of Political Science

Volumn 51, Issue 4, 2007, Pages 835-852

  Carpenter, Daniel ^a   Ting, Michael M ^b  

^a HARVARD UNIVERSITY   (United States)

^b Columbia University ^*

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34948867661     PISSN: 00925853     EISSN: 15405907     Source Type: Journal    
DOI: 10.1111/j.1540-5907.2007.00284.x     Document Type: Article

References (25)

1. Allison, G. T. 1971. Essence of Decision: Explaining the Cuban Missile Crisis. Boston : Little, Brown.
2. Alt, J., R. Calvert, and B. Humes. 1988 Reputation and Hegemonic Stability: A Game-Theoretical Analysis American Political Science Review 82 (1 445 66.
3. Avorn, J. 2004. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York : Knopf.
4. Bendor, J. 1985. Parallel Systems: Redundancy in Government. Berkeley : University of California Press.
5. Bendor, J., and S. Kumar. 2005 The Perfect Is the Enemy of the Best: Adaptive versus Optimal Organizational Reliability Journal of Theoretical Politics 17 (1 5 39.
6. Calvert, R. 1987 Reputation and Legislative Leadership Public Choice 55 (1-2 81 119.
7. Carpenter, D. P. 2002 Groups, the Media, Agency Waiting Costs and FDA Drug Approval American Journal of Political Science 46 (3 490 505.
8. Carpenter, D. P. 2004 Protection without Capture: Dynamic Product Approval by a Politically Responsive, Learning Regulator American Political Science Review 98 (4 613 31.
9. Carpenter, D. P., M. Chernew, A. M. Fendrick, and D. Smith. 2003 Approval Times for New Drugs: Does the Source of Funding for FDA Staff Matter? Health Affairs (Web Exclusive), W3-618-624.
10. Dixit, A., and R. Pindyck. 1994. Investment Under Uncertainty. Princeton, NJ : Princeton University Press.
11. Dranove, D., and D. Meltzer. 1994 Do Important Drugs Reach the Market Sooner? RAND Journal of Economics 25 (3 402 23.
12. Heimann, C. F. L. 1997. Acceptable Risks: Politics, Policy, and Risky Technologies. Ann Arbor : University of Michigan Press.
13. Hilts, P. 2003. Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation. New York : Knopf.
14. Kamien, M. I., and N. L. Schwartz. 1972 Timing of Innovations under Rivalry Econometrica 40 (1 43 60.
15. Landau, M. 1969 Redundancy, Rationality, and the Problem of Duplication and Overlap Public Administration Review 29 (4 346 58.
16. Moscarini, G., and L. Smith. 2001 The Optimal Level of Experimentation Econometrica 69 (6 1629 44.
17. Olson, M. 2000 Regulatory Reform and Bureaucratic Responsiveness to Firms: The Impact of User Fees in the FDA Journal of Economics and Management Strategy 9 (3 363 95.
18. Peltzman, S. 1973 An Evaluation of Consumer Protection Regulation: The 1962 Drug Amendments Journal of Political Economy 81 (5 1049 91.
19. Peltzman, S. 1976. Regulation of Pharmaceutical Innovation: The 1962 Amendments. Washington, DC : American Enterprise Institute.
20. Quirk, P. J. 1980 Food and Drug Administration In The Politics of Regulation, ed. J. Q. Wilson. New York : Basic Books, pp. 191 235.
21. Reinganum, J. F. 1982 A Dynamic Game of R and D: Patent Protection and Competitive Behavior Econometrica 50 (3 671 88.
22. Simon, H. A. 1968. Administrative Behavior. New York : Free Press.
23. Ting, M. M. 2003 A Strategic Theory of Bureaucratic Redundancy American Journal of Political Science 47 (2 274 92.
24. United States General Accounting Office. 1990 FDA Drug Review - Postapproval Risks 1976-1985 GAO/PEMD-90-15.
25. Wardell, W. M., and L. Lasagna. 1975. Regulation and Drug Development. Washington, DC : American Enterprise Institute.